StreetInsider.com News Articles

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Thu, 16 Jul 2026 23:48:00 -0400

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far
Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027
Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program
Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network
Participants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical

Plains All American (PAA) PT Raised to $23 at Barclays

Thu, 16 Jul 2026 05:18:55 -0400

Barclays analyst Theresa Chen raised the price target on Plains All American (NASDAQ: PAA) to $23.00 (from $21.00) while maintaining a Underweight rating.

Plains All American (PAA) PT Raised to $25 at Truist Securities

Wed, 15 Jul 2026 07:10:34 -0400

Truist Securities analyst Neal Dingmann raised the price target on Plains All American (NASDAQ: PAA) to $25.00 (from $23.00) while maintaining a Buy rating.

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).

The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP

Fri, 10 Jul 2026 11:22:43 -0400

Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.

For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating

Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions and Timing of Second Quarter 2026 Earnings

Mon, 06 Jul 2026 16:30:00 -0400

HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) announced today their quarterly distributions with respect to the second quarter of 2026 and also announced timing of second quarter 2026 earnings.

Second Quarter Distribution Declaration

PAA and PAGP announced the following quarterly cash distributions, each of which will be payable on August 14, 2026, to holders of the respective securities at the close of business on July 31, 2026:

PAA Common Units